The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations
Open accessAbstract
Poly(ADP-ribose) polymerase-1 (PARP-1), when activated by DNA damage, promotes both cell death and inflammation. Here we report that PARP-1 enzymatic activity is directly inhibited by minocycline and other tetracycline derivatives that have previously been shown to have neuroprotective and anti-inflammatory actions. These agents were evaluated by using cortical neuron cultures in which PARP-1 activation was induced by the genotoxic agents N -methyl- N ′-nitro- N -nitrosoguanidine (MNNG) or 3-morpholinosydnonimine (SIN-1). In both conditions, neuronal death was reduced by >80% either by 10 μM 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone, an established PARP inhibitor, or by 100 nM minocycline. Neuronal NAD + depletion and poly(ADP-ribose) formation, which are biochemical markers of PARP-1 activation, were also blocked by 100 nM minocycline. A direct, competitive inhibition of PARP-1 by minocycline ( K i = 13.8 ± 1.5 nM) was confirmed by using recombinant PARP-1 in a cell-free assay. Comparison of several tetracycline derivatives showed a strong correlation ( r 2 = 0.87) between potency as a PARP-1 inhibitor and potency as a neuroprotective agent during MNNG incubations, with the rank order of potency being minocycline > doxycycline > demeclocycline > chlortetracycline. These compounds are known to have other actions that could contribute their neuroprotective effects, but at far higher concentrations than shown here to inhibit PARP-1. The neuroprotective and antiinflammatory effects of minocycline and other tetracycline derivatives may be attributable to PARP-1 inhibition in some settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
A Role of Poly (ADP-Ribose) Polymerase in NF- B Transcriptional Activation
Hassa, P. O., & Hottiger, M. O. (1999) · Biological Chemistry · doi:10.1515/bc.1999.118 · Cited by 296
Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage
Morimoto, N., Shimazawa, M., Yamashima, T., Nagai, H., & Hara, H. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.062 · Cited by 137
Cited by
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“…production of IL-1 and NO, has been shown to inhibit p38 MAPK as well as poly(ADP-ribose) polymerase-1, which along with inhibition of NF-kB (see below), may serve as the basis for its anti-inflammatory efficacy (Tikka et al, 2001; Tikka and Koistinaho, 2001; Si et al, 2004; Alano et al, 2006).”
BackgroundMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Ziebell, J. M., & Morganti-Kossmann, M. C. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2009.10.016 · Cited by 667
Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency
Yang, Y., Liu, B., Xu, J., Wang, J., Wu, J., Shi, C., Xu, Y., Dong, J., Wang, C., Lai, W., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.005 · Cited by 502
NAD + Depletion Is Necessary and Sufficient forPoly(ADP-Ribose) Polymerase-1-Mediated Neuronal Death
Alano, C. C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T. M., & Swanson, R. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5552-09.2010 · Cited by 439
“Cell fixation and immunostaining for AIF and PAR were performed as described previously (Alano et al., 2004, 2006), using anti-AIF polyclonal antibody (Sigma-Aldrich) at a 1:1500 dilution and anti-PAR polyclonal antibody (Trevigen) at a 1:2000 dilution.”
MethodInfluentialSelf-citationMicroglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
Self-citationEctopic discharge in Aβ afferents as a source of neuropathic pain
Devor, M. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-1724-6 · Cited by 387
Isermann, B., Vinnikov, I. A., Madhusudhan, T., Herzog, S., Kashif, M., Blautzik, J., Corat, M. A. F., Zeier, M., Blessing, E., Oh, J., et al. (2007) · Nature Medicine · doi:10.1038/nm1667 · Cited by 385
The mitochondrial death pathway: a promising therapeutic target in diseases
Gupta, S., Kass, G. E. N., Szegezdi, E., & Joseph, B. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00697.x · Cited by 278
Prospects for Minocycline Neuroprotection
Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276
Sex differences in the brain: Implications for behavioral and biomedical research
Choleris, E., Galea, L. A. M., Sohrabji, F., & Frick, K. M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.005 · Cited by 214
Evidence for Neuroinflammatory and Microglial Changes in the Cerebral Response to Sleep Loss
Wisor, J. P., Schmidt, M. A., & Clegern, W. C. (2011) · Sleep · doi:10.1093/sleep/34.3.261 · Cited by 141
Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β
Kauppinen, T. M., Suh, S., Higashi, Y., Berman, A. E., Escartin, C., Won, S., Wang, C., Cho, S.-H., Gan, L., & Swanson, R. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-152 · Cited by 112
“These results are consistent with prior reports that minocycline, which is a potent PARP inhibitor [62], likewise does not block Ab phagocytosis by microglia [63,64].”
ResultSelf-citationMinocycline development for acute ischemic stroke
Fagan, S. C., Cronic, L. E., & Hess, D. C. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0072-6 · Cited by 100
“Its anti-apoptotic effects are produced through reduction of caspase-1 activation, downregulation of cytochrome c release from mitochondria [13], and inhibition poly(ADP-ribose) polymerase-1 at nanomolar concentrations [14].”
BackgroundRole of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment
Raison, C. L., & Miller, A. H. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343966 · Cited by 88
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
“Indeed, the fact that minocycline, like PARP inhibitors, has both neuroprotective and anti-inflammatory effects may stem from the fact minocycline is itself a potent PARP inhibitor [55].”
BackgroundSelf-citationMinocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model
Huang, T.-Y., Chu, H.-C., Lin, Y.-L., Ho, W.-H., Hou, H.-S., Chao, Y.-C., & Liao, C.-L. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.041 · Cited by 59
A pilot open-label trial of minocycline in patients with autism and regressive features
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-9 · Cited by 58
Accelerated Aging during Chronic Oxidative Stress: A Role for PARP-1
Boesten, D. M. P. H. J., de Vos-Houben, J. M. J., Timmermans, L., den Hartog, G. J. M., Bast, A., & Hageman, G. J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/680414 · Cited by 37
Yuan, T., Manohar, K., Latorre, R., Orock, A., & Greenwood-Van Meerveld, B. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.020 · Cited by 35
Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors
Imbesi, M., Uz, T., Manev, R., Sharma, R. P., & Manev, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.006 · Cited by 34
“Several CNS-relevant molecular pathways have been onsidered as possible mediators of minocycline’s actions in the rain [1,5,13,19,20].”
Metadata
- Authors
- Alano, C. C., Kauppinen, T. M., Valls, A. V., & Swanson, R. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-06-20
- Volume
- 103
- Issue
- 25
- Pages
- 9685-9690
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2077926137
- Cited by
- 229
- References
- 7
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.